Paracetamol for injection: new formulation. New formulation: why so widely used?
Prescrire International 12(67): 178
2003
ISSN/ISBN: 1167-7422 PMID: 14619896 Document Number: 555050
Paracetamol for injection appears to cause fewer local reactions than propacetamol. However, the added therapeutic value of the parenteral route is not supported by a thorough comparative evaluation. The widespread use of this product in hospitals is worrying
Document emailed within 1 workday
Related Documents
2002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-1782003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
Jain, N.K.; Agrawal, R.K.; Singhai, A.K. 1990: Formulation of aqueous injection of carbamazepine Die Pharmazie 45(3): 221-222
Nahata, M.C.; Roberts, D.L. 1987: Formulation of caffeine injection for I.v. administration American Journal of Hospital Pharmacy 44(6): 1308; 1312
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Guo, Y.; Chen, X.; Zhao, Y.; Sun, J. 1996: Screening for the new formulation of 25% ascorbic acid injection and studies on its stability Hua Xi Yi Ke da Xue Xue Bao 27(3): 327-331
Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Oberpichler-Schwenk, H. 2013: Progress through formulation Medizinische Monatsschrift für Pharmazeuten 36(7): 243
1984: Toothpaste formulation British Dental Journal 157(3): 84-85
Allegro, L.A. 1990: On the formulation of interpretations International Journal of Psycho-Analysis 71: 421-433
Akers, M.J. 2014: Formulation and Stability of Solutions International Journal of Pharmaceutical Compounding 20(1): 41-45
Medvedev, I.A. 2005: Conditionalism and formulation of cause of death Arkhiv Patologii 67(2): 60-64
Slifirski, P.; Szelejewski, W.ła.; Grynkiewicz, G.; Gubernator, J.; Kozubek, A. 2003: Liposomal formulation of idarubicin Acta Poloniae Pharmaceutica 60(2): 138-140
Bishop, M.C. 1996: Formulation of guidelines for treatment Lancet 347(8997): 331
Casado, P.; Torreira, C.; Oujo, E.; Esteban, P.; Albo, C.; Diaz, R.; M.A. Andrade 2010: New Liposomal Cytarabine Formulation in CSF Clinical Laboratory 56(1-2): 69-70
Chou, S.T.; Robinson, G.A. 1972: Formulation of a laboratory rabbit diet Laboratory Animal Science 22(1): 48-55
Hora, M.S.; Rana, R.K.; Wilcox, C.L.; Katre, N.V.; Hirtzer, P.; Wolfe, S.N.; Thomson, J.W. 1992: Development of a lyophilized formulation of interleukin-2 Developments in Biological Standardization 74: 295-303; Discussion: 303-306